Parkview Health

Parkview Health Research Repository
Other Specialties

Parkview Research Center

10-28-2021

Endoscopic ultrasound-guided vascular interventions: Current
insights and emerging techniques
Rupinder Mann MD
Hermant Goyal MD
Abhilash Perisetti MD
Parkview Health, abhilash.perisetti@gmail.com

Saurabh Chandan MD
Sumant Inamdar MD

See next page for additional authors

Follow this and additional works at: https://researchrepository.parkviewhealth.org/other
Part of the Gastroenterology Commons

Recommended Citation
Mann R, Goyal H, Perisetti A, Chandan S, Inamdar S, Tharian B. Endoscopic ultrasound-guided vascular
interventions: Current insights and emerging techniques. World J Gastroenterol 2021; 27(40): 6874-6887

This Article is brought to you for free and open access by the Parkview Research Center at Parkview Health
Research Repository. It has been accepted for inclusion in Other Specialties by an authorized administrator of
Parkview Health Research Repository. For more information, please contact julie.hughbanks@parkview.com.

Authors
Rupinder Mann MD, Hermant Goyal MD, Abhilash Perisetti MD, Saurabh Chandan MD, Sumant Inamdar
MD, and Benjamin Tharian MD

This article is available at Parkview Health Research Repository: https://researchrepository.parkviewhealth.org/other/
37

ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

World Journal of
Gastroenterology
World J Gastroenterol 2021 October 28; 27(40): 6737-7004

Published by Baishideng Publishing Group Inc

WJ G

World Journal of
Gastroenterology

Contents

Weekly Volume 27 Number 40 October 28, 2021

FRONTIER
6737

Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen
and for how long?
Ahumada A, Rayón L, Usón C, Bañares R, Alonso Lopez S

OPINION REVIEW
6750

Higher doses of ascorbic acid may have the potential to promote nutrient delivery via intestinal
paracellular absorption
Sequeira IR

EVIDENCE REVIEW
6757

Venous and arterial thromboembolism in patients with inflammatory bowel diseases
Stadnicki A, Stadnicka I

REVIEW
6775

Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer
Ostios-Garcia L, Villamayor J, Garcia-Lorenzo E, Vinal D, Feliu J

6794

Artificial intelligence in gastroenterology: A state-of-the-art review
Kröner PT, Engels MM, Glicksberg BS, Johnson KW, Mzaik O, van Hooft JE, Wallace MB, El-Serag HB, Krittanawong C

MINIREVIEWS
6825

Emerging artificial intelligence applications in liver magnetic resonance imaging
Hill CE, Biasiolli L, Robson MD, Grau V, Pavlides M

6844

Role of human nucleoside transporters in pancreatic cancer and chemoresistance
Carter CJ, Mekkawy AH, Morris DL

6861

Management of hepatitis B and C in special population
Kulkarni AV, Duvvuru NR

6874

Endoscopic ultrasound-guided vascular interventions: Current insights and emerging techniques
Mann R, Goyal H, Perisetti A, Chandan S, Inamdar S, Tharian B

WJG

https://www.wjgnet.com

I

October 28, 2021

Volume 27

Issue 40

World Journal of Gastroenterology

Contents

Weekly Volume 27 Number 40 October 28, 2021

ORIGINAL ARTICLE
Basic Study
6888

Metabolomics of Fuzi-Gancao in CCl4 induced acute liver injury and its regulatory effect on bile acid profile
in rats
Wang MF, Zhao SS, Thapa DM, Song YL, Xiang Z

6908

Transforming growth factor beta-1 upregulates glucose transporter 1 and glycolysis through canonical and
noncanonical pathways in hepatic stellate cells
Zhou MY, Cheng ML, Huang T, Hu RH, Zou GL, Li H, Zhang BF, Zhu JJ, Liu YM, Liu Y, Zhao XK

Retrospective Cohort Study
6927

Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in
chronic hepatitis B
Chi XM, Wang XM, Wang ZF, Wu RH, Gao XZ, Xu HQ, Ding YH, Niu JQ

6939

Long-term follow-up of liver alveolar echinococcosis using echinococcosis multilocularis ultrasound
classification
Schuhbaur J, Schweizer M, Philipp J, Schmidberger J, Schlingeloff P, Kratzer W

Observational Study
6951

Hepatic and gastrointestinal disturbances in Egyptian patients infected with coronavirus disease 2019: A
multicentre cohort study
Shousha HI, Afify S, Maher R, Asem N, Fouad E, Mostafa EF, Medhat MA, Abdalazeem A, Elmorsy H, Aziz MM,
Mohammed RS, Ibrahem M, Elgarem H, Omran D, Hassany M, Elsayed B, Abdelaziz AY, El Kassas M

6967

Factors affecting anxiety, depression, and self-care ability in patients who have undergone liver
transplantation
Akbulut S, Ozer A, Saritas H, Yilmaz S

META-ANALYSIS
6985

Prophylactic transcatheter arterial embolization reduces rebleeding in non-variceal upper gastrointestinal
bleeding: A meta-analysis
Boros E, Sipos Z, Hegyi P, Teutsch B, Frim L, Váncsa S, Kiss S, Dembrovszky F, Oštarijaš E, Shawyer A, Erőss B

LETTER TO THE EDITOR
7000

Gastrointestinal and hepatic involvement during COVID-19 pandemic: A focus on pediatric population
and possible future implications
Sica R, Pennoni S, Penta L, Riccioni S, Di Cara G, Verrotti A

WJG

https://www.wjgnet.com

II

October 28, 2021

Volume 27

Issue 40

World Journal of Gastroenterology

Contents

Weekly Volume 27 Number 40 October 28, 2021

ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, Pietro Fusaroli, MD, Associate Professor, Chief,
Gastrointestinal Unit, University of Bologna at the Hospital of Imola, Via Montericco 4, Imola 40026, Italy.
pietro.fusaroli@unibo.it

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers
from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical
research articles and communicate their research findings online. WJG mainly publishes articles reporting research
results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics
including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal
oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as
SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2021
edition of Journal Citation Report® cites the 2020 impact factor (IF) for WJG as 5.742; Journal Citation Indicator: 0.79;
IF without journal self cites: 5.590; 5-year IF: 5.044; Ranking: 28 among 92 journals in gastroenterology and
hepatology; and Quartile category: Q2. The WJG’s CiteScore for 2020 is 6.9 and Scopus CiteScore rank 2020:
Gastroenterology is 19/136.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Jia-Hui Li; Production Department Director: Yu-Jie Ma; Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL

INSTRUCTIONS TO AUTHORS

World Journal of Gastroenterology

https://www.wjgnet.com/bpg/gerinfo/204

ISSN

GUIDELINES FOR ETHICS DOCUMENTS

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

https://www.wjgnet.com/bpg/GerInfo/287

LAUNCH DATE

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

October 1, 1995

https://www.wjgnet.com/bpg/gerinfo/240

FREQUENCY

PUBLICATION ETHICS

Weekly

https://www.wjgnet.com/bpg/GerInfo/288

EDITORS-IN-CHIEF

PUBLICATION MISCONDUCT

Andrzej S Tarnawski, Subrata Ghosh

https://www.wjgnet.com/bpg/gerinfo/208

EDITORIAL BOARD MEMBERS

ARTICLE PROCESSING CHARGE

http://www.wjgnet.com/1007-9327/editorialboard.htm

https://www.wjgnet.com/bpg/gerinfo/242

PUBLICATION DATE

STEPS FOR SUBMITTING MANUSCRIPTS

October 28, 2021

https://www.wjgnet.com/bpg/GerInfo/239

COPYRIGHT

ONLINE SUBMISSION

© 2021 Baishideng Publishing Group Inc

https://www.f6publishing.com

© 2021 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

WJG

https://www.wjgnet.com

III

October 28, 2021

Volume 27

Issue 40

WJ G

World Journal of
Gastroenterology

Submit a Manuscript: https://www.f6publishing.com

World J Gastroenterol 2021 October 28; 27(40): 6874-6887

DOI: 10.3748/wjg.v27.i40.6874

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

MINIREVIEWS

Endoscopic ultrasound-guided vascular interventions: Current
insights and emerging techniques
Rupinder Mann, Hemant Goyal, Abhilash Perisetti, Saurabh Chandan, Sumant Inamdar, Benjamin Tharian

ORCID number: Rupinder Mann
0000-0001-9139-7411; Hemant Goyal
0000-0002-9433-9042; Abhilash
Perisetti 0000-0003-4074-6395;
Saurabh Chandan 0000-0002-26616693; Sumant Inamdar 0000-00021002-2823; Benjamin Tharian 00000002-7797-3738.

Author contributions: Perisetti A,
Goyal H and Mann R concepted
and designed the article, did a
literature search; Mann R finished
the first draft; all authors critically
revised and edited manuscript.

Conflict-of-interest statement:
Rupinder Mann, Hemant Goyal,
Abhilash Perisetti, Saurabh
Chandan, Sumant Inamdar has
nothing to disclose; Benjamin
Tharian acts as a consultant to
Boston Scientific and Medtronic
which are not relevant for this
manuscript.

Open-Access: This article is an
open-access article that was
selected by an in-house editor and
fully peer-reviewed by external
reviewers. It is distributed in
accordance with the Creative
Commons Attribution
NonCommercial (CC BY-NC 4.0)
license, which permits others to
distribute, remix, adapt, build
upon this work non-commercially,
and license their derivative works
on different terms, provided the
original work is properly cited and

WJG

Rupinder Mann, Department of Internal Medicine, Saint Agnes Medical Center, Fresno, CA
93730, United States
Hemant Goyal, Department of Internal Medicine, The Wright Center for Graduate Medical
Education, Scranton, PA 18503, United States
Abhilash Perisetti, Department of Gastroenterology and Hepatology, The University of
Arkansas for Medical Sciences, Little Rock, AR 72205, United States
Saurabh Chandan, Department of Gastroenterology and Hepatology, CHI Creighton University
Medical Center, Omaha, NE 68107, United States
Sumant Inamdar, Benjamin Tharian, Department of Internal Medicine, Gastroenterology and
Hepatology Division, University of Arkansas for Medical Sciences, Little Rock, AR 72205,
United States
Corresponding author: Abhilash Perisetti, FACP, MBBS, MD, Academic Fellow, Department
of Gastroenterology and Hepatology, The University of Arkansas for Medical Sciences, 4301
W Markham St, Little Rock, AR 72205, United States. abhilash.perisetti@gmail.com

Abstract
Endoscopic ultrasound (EUS) is one of the significant breakthroughs in the field of
advanced endoscopy. In the last two decades, EUS has evolved from a diagnostic
tool to a real-time therapeutic modality. The luminal gastrointestinal (GI) tract
provides a unique opportunity to access multiple vascular structures, especially in
the mediastinum and abdomen, thus permitting a variety of EUS-guided vascular
interventions. The addition of the doppler and contrast-enhanced capability to
EUS has further helped provide real-time visualization of blood flow in vessels
through the GI tract. EUS-guided vascular interventions rely on standard
endoscopic accessories and interventional tools such as fine-needle aspiration
needles and fine-needle biopsy. EUS allows the visualization of various structures
in real-time by differentiating tissue densities and vascularity, thus, avoiding
radiation exposure. EUS-guided techniques also allow real-time microscopic
examination after target biopsy. Furthermore, many necessary interventions can
be done during the same procedure after diagnosis. This article provides an
overview of EUS-guided vascular interventions such as variceal, non-variceal
bleeding interventions, EUSguided portal vein (PV) access with the formation of
an intrahepatic portosystemic shunt, and techniques related to diagnosis of GI
malignancies. Furthermore, we discuss current insights and future outlook of
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therapeutic modalities like PV embolization, PV sampling, angiography, drug
administration, and portal pressure measurement.
Key Words: Endoscopic ultrasound; Vascular intervention; Esophageal varices; Gastric
varices; Portal vein; Therapeutic endoscopy
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Core Tip: Endoscopic ultrasound (EUS) technology has evolved rapidly in clinical
practice, first as merely a diagnostic tool and now a therapeutic modality. EUS-guided
interventions involve combining real-time imaging capability with invasive therapeutic
interventions. The gastrointestinal (GI) tract has proximity to various vascular
structures in the abdomen and mediastinum and thus provides a unique window to
access these structures with EUS to render EUS-guided vascular interventions. Herein,
this article provides an overview of EUS-guided vascular interventions for GI bleeding,
portal vein access, and therapeutic implications, tumor diagnosis, and access to non-GI
structures.

Citation: Mann R, Goyal H, Perisetti A, Chandan S, Inamdar S, Tharian B. Endoscopic
ultrasound-guided vascular interventions: Current insights and emerging techniques. World J
Gastroenterol 2021; 27(40): 6874-6887
URL: https://www.wjgnet.com/1007-9327/full/v27/i40/6874.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i40.6874

INTRODUCTION
Endoscopic ultrasound (EUS) is a minimally invasive specialized procedure that
blends endoscopy with ultrasound. The endoscope allows visualizing the
gastrointestinal (GI) tract lining, and ultrasound allows visualization of the GI tract
walls, surrounding organs, and blood vessels with high-frequency waves. Three
different types of echoendoscopes are available: Linear, radial, and mini-probes.
Linear echoendoscopes are preferred for pancreaticobiliary interventions such as
acquiring tissue, drainage of collections, and injections. Radial echoendoscopes are
preferred for the staging of esophageal and gastric cancers[1,2]. Mini probes are more
useful in diagnosing mucosal malignancy, pancreaticobiliary diseases (such as
malignancy or stricture) because of their high frequency[1]. EUS can visualize both
solid and fluid structures in the GI lumen and extraluminal. Various structures
accessible with EUS include the luminal wall of the GI tract (esophagus, stomach,
duodenum, and rectum), liver, pancreas, gallbladder, biliary tree, mediastinum, and
lymph nodes. In addition, EUS can identify various arterial and venous vascular
structures in proximity to the GI tract are accessible. Feeding vessels from small
branches of vessels and aberrant vascular shunts can also be visualized by EUS[2,3].
Since the introduction of EUS in 1980 for diagnostic purposes, significant evolution
has occurred (Figures 1 and 2). Its application on humans dates back to 1982[4]. This
evolved in 1991 when EUS-guided fine-needle aspiration (FNA) was first introduced,
and it allowed to do therapeutic interventions outside the lumen of the GI tract[5]. In
1996, EUS-guided cholangiography and EUS-guided biliary drainage were introduced
[6]. Furthermore, the role of EUS expanded rapidly over the last 20 years from the
diagnostic to the therapeutic tool as it provides direct visualization, access to
structures within and outside the GI tract. Several new advancements in EUS-guided
vascular procedures have emerged due to the proximity of many blood vessels to the
GI tract and the ability to deliver precise real-time interventions. It has been further
expanded to target gastric variceal bleeding by cyanoacrylate (CYA) injection[7]. In
2008, EUS-guided glue injection and micro coil embolization were used to treat a
patient with refractory gastric variceal bleeding. Additionally, EUS can obtain realtime portal pressures in patients suspected of portal hypertension (PH) and obtain
liver core biopsies to evaluate for fibrosis in one setting. Given its ability to access the
portal vein (PV), interventions such as PV thrombectomy have been possible. Given
these advances, we aim to discuss updates and emerging trends in EUS related
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Figure 1 Endoscopic ultrasound history. EUS: Endoscopic ultrasound; FNA: Fine-needle aspiration; Rx: Treatment.

Figure 2 Different types of endoscopic ultrasound guided vascular interventions. PV: Portal vein; EUS: Endoscopic ultrasound; GI: Gastrointestinal.

vascular interventions.

ROLE OF EUS IN THE MANAGEMENT OF GI BLEEDING
Variceal bleeding
Esophageal varices: Endoscopic band ligation (EBL) is the preferred treatment for
bleeding and non-bleeding esophageal varices. However, endoscopic sclerotherapy is
an additional treatment that is still used, especially when EBL is not feasible[8].
Although these therapies are successful, the rate of recurrent bleeding can range up to
15%-65%[9]. The higher recurrence is most likely due to failure to treat perforating and
collateral vessels. Echoendoscope provides benefits over endoscope due to its ability to
visualize and target these high-risk vessels under direct visualization[10,11]. EUSguided sclerotherapy for esophageal varices was first described in 2000 by Lahoti et al
[12] in a study of 5 patients. A sclerosing agent such as sodium morrhuate was injected
into target perforating vessels under EUS guidance until complete blood flow
cessation was confirmed with the doppler. A mean of 2.2 sessions (range 2-3 sessions)
were required to achieve the complete eradication of varices. No recurrence of
bleeding or death was reported during 15 mo follow-up. Only one patient developed
esophageal stricture, which was managed with balloon dilation[12].
The above study showed comparable results of EUS-guided sclerotherapy for
esophageal varices. Therefore, EBL is still a preferred treatment for esophageal varices.
Large, randomized trials are needed to show the clinical benefits of EUS-guided sclerotherapy compared to EBL to consider it as one of the first-line treatments.
Gastric varices: Although gastric varices (GV) are less common than esophageal
varices, it affects around 20% of patients with PH[13,14]. GV can occasionally cause
bleeding, leading to iron deficiency anemia, and the risk of rebleeding (34%-89%) is
much higher than compared to esophageal varices (15%-65%)[13]. There are no wellWJG
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established treatment guidelines for the management of GV compared to esophageal
varices[15]. EBL is not recommended for managing GV as they are larger in size, with
thick overlying gastric mucosa making it difficult to band. EBL of GV can lead to lifethreatening bleeding due to post-band ulcerations, developed due to a failure to
capture the contralateral wall of varices during the procedure[16]. In a study of 22
patients with bleeding GV treated with EBL, 18.2% developed early rebleeding even
after complete hemostasis was achieved in all cases on EBL[17]. Endoscopic sclerosing
therapy should also be avoided in bleeding GV as it provides only temporary control
of bleed and a higher incidence of adverse events like gastric ulcerations, perforations,
and rebleeding in 37%–53% of cases[18 ].
Glue therapy with CYA is the primary treatment of choice for GV. It was first
described in 1986 as it has higher rates (> 90%) of achieving hemostasis and a lower
rate of rebleeding (0%-40%) compared to other therapies (EBL and sclerotherapy)[19,
20]. However, there are reports of significant adverse effects associated with CYA
injections like systemic embolization (cardiac embolism, pulmonary embolism, splenic
vein thrombosis, splenic artery embolism, renal vein thrombosis, and cerebral infarct),
which is thought to be related to the volume of CYA injection[21]. EUS assists in both
the diagnosis and treatment of GV. It helps in diagnosis and allows a precise
evaluation of pathological vessels, improving therapeutic targeting. Color doppler also
permits to differentiation of GV from other structures and can help confirm
eradication of varices. EUS has provided us a new array of treatment options, including coil embolization with or without glue therapy and thrombin injection etc., in the
treatment of GV[13,20].
Glue therapy. Endoscopic-CYA injection has been shown to control bleeding, but
there is a high recurrence of bleeding, probably due to incomplete obliteration of
varices. EUS-guided CYA glue injection can minimize recurrent bleeding and decrease
CYA volume by directly visualizing the perforating vessels, thus more precise
obliteration of varices. Theoretically, the risk of embolization also decreases as it
allows precise CYA injection into the target vessel[7].
A total of six patients with GV, including four for secondary prophylaxis, were
treated with EUS-guided coil embolization followed by CYA glue injection in a singlecenter retrospective study. Complete eradication of GV was achieved in 3 patients.
One patient had pulmonary embolism as a complication of CYA glue injection[22]. In a
large single-center study, 40 patients underwent EUS-guided n-butyl-2-CYA for GV.
Out of 40 patients, 13 patients were treated during active bleeding and another 23
within 24 h of bleeding. Thus, bleeding was acutely controlled in 100% of cases after
treatment with EUS-guided n-butyl-2-CYA therapy. Only six patients required
additional intervention for long-term management (Table 1)[23].
In a single-center study, 40 patients with actively/recently bleeding or high-risk GV
treated with direct endoscopic injection of CYA were compared with 64 patients
treated prospectively with EUS-guided fine needle injection CYA. Gastroesophageal
varices type 2 was the most common type of varices seen in both groups. During the
procedure, a greater number of varices were obliterated in EUS-guided fine needle
injection of the CYA group (1.6 ± 0.7) than the direct endoscopic injection of the CYA
group (1.1 ± 0.4, P < 0.001). Whereas the mean volume of CYA was injected more in
the direct endoscopic injection-CYA group (3.3 ± 1.3 mL) compared to EUS-guided
fine needle injection of the CYA group (2.0 ± 0.8 mL, P < 0.001). Overall postprocedure GV rebleeding (23.7% vs 8.8%, P = 0.045) and non-GV-related GI bleeding
(GIB) (27.5% vs 10.9%, P = 0.030) were found to be higher in the direct endoscopic
injection of CYA group compared to EUS-guided fine needle injection of CYA group.
No significant difference was found in the overall rate of adverse events in the direct
endoscopic injection of CYA group (17.5%) and EUS-guided fine needle injection of
CYA (20.3%, P = 0.361)[24]. EUS-guided glue injection appears to be safe and effective
in decreasing the risk of rebleeding in patients with active or recent bleeding GV when
compared to the endoscopic injection of CYA.
Coil embolization. EUS-guided coil application is another treatment modality for
GV. Coils are commonly used for various interventional radiology procedures
(Table 1). These micro coils can obliterate GV and avoids adverse effects associated
with CYA use, such as embolization coils are made up of light metal alloy and are
covered with synthetic fibers to induce clot formation and subsequent hemostasis.
Furthermore, fibers can act as a scaffold for CYA if injected during the same
procedure. Varices are identified and punctured through standard FNA size needles
like 19G (0.035-inch coil) or a 22G (0.018-inch coil). These coils are then advanced from
the needle into varix using the stylet as a pusher. The coil sizes are selected based on
the size of varix[25,26].
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Table 1 Endoscopic ultrasound-guided gastric varices treatment
Type of
Intervention

Year Ref.

Number of
patients, n (%)

Follow up
(mo)

Obliteration of
varices/Clinical success %

Recurrent
bleeding rate %

Adverse
events %

CYA glue

2019

Lôbo et al[13]

16

9.9

75%

-

50%

CYA glue

2014

Gubler and
Bauerfeind[23]

40

-

100%

15%

5%

CYA glue

2019

Bick et al[24]

64

6.6

96.9%

8.8%

17.5%

CYA glue

2013

Romero-Castro et
al[26]

19

6

94.7%

0%

57.9%

CYA glue

2018

Krill et al[62]

10

4

100%

-

0%

Coil

2013

Romero-Castro et
al[26]

11

6

90.9%

0%

9.1%

Coil

2018

Krill et al[62]

6

4

100%

-

0%

Coil

2010

Romero-Castro et
al[63]

4

5 (1-3)

75%

0%

0%

Coil and CYA
Glue

2019

Lôbo et al[13]

16

9.9

73.3%

-

25%

Coil and CYA
Glue

2019

Kozieł et al[14]

16

10.9

100%

-

37.5%

Coil and CYA
Glue

2018

Krill et al[62]

12

4

100%

-

8%

CYA: Cyanoacrylate.

A retrospective multicenter study compared EUS-guided CYA injection (n = 19) to
EUS-guided coil embolization (n = 11) patients with GV. There was no statistically
significant difference in obliteration rate, the mean number of sessions required, and
recurrence noted during follow-up. However, adverse events were reported to be
higher in the CYA group in [11/19 (57%)] when compared to EUS-guided coil
embolization [1/11 (9.1%), P < 0.01]. A post-procedure computed tomography (CT)
scan was performed in all patients, and nine patients in the CYA group were found to
have asymptomatic glue embolism on imaging[26] (Table 1). This was the first study to
compare coil embolization and CYA directly. Both procedures showed comparable
results in terms of GV obliteration, but fewer adverse events were noted with coil
embolization.
In another study, ten patients with GV underwent EUS-guided coil embolization
and then reinforcement by gelatin sponges. Nine patients had either active bleeding or
recently bled GV. A 100% obliteration of GV was achieved. Patients were followed for
six mo, and only 1/10 patients developed severe abdominal pain as a complication.
Further large prospective studies are needed describing its direct comparison with
other treatment modalities like CYA or CYA and coil embolization combined[27].
Combined coiling and glue therapy. Although endoscopic CYA injection is
considered primary therapy for GV, it is associated with systemic glue embolization.
Synthetic fibers in the covering of coils function as a scaffold to keep CYA in varices;
thus, a decrease of CYA reagent is needed to eradicate gastric fundal varices (GFV)
and also may reduce the risk of glue embolization. In another study by Kozieł et al[14],
four patients were treated with coils, and 12 patients were treated with EUS-guided
coil and CYA injection. These patients were followed for an average of 327 d. The
technical success rate was 94%, and the mean number of CYA volume and coils
needed per procedure was 2 mL and 1.7, respectively. No serious complications like
embolization or death were noted (Table 1).
A randomized pilot trial was conducted comparing the safety and efficacy of EUSguided coil and CYA (n = 16) to EUS-guided CYA in GV patients, and these patients
were followed for an average of 9.9 mo. EUS doppler was done in all cases to
determine flow within varix after the procedure, and thoracic and abdomen CT was
done in all cases 1 wk after the procedure. Repeat CT scans were done in symptomatic
cases only afterward. In the EUS-guided coil and CYA vs EUS-guided CYA group, the
total reduction inflow in the treated vessel was 37.5% vs 50% (P = 0.476) and 73% vs
80% (P = 1) immediately and at 30 d after the procedure, respectively. In addition,
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asymptomatic pulmonary embolism was found to be in 25%, and 50% cases (P = 0.144)
in EUS-guided combined coil and CYA and EUS-guided CYA, respectively[13]
(Table 1).
A metanalysis and systematic review was conducted comparing EUS-guided CYA
injection, EUS-guided coil embolization and CYA injection combined, and EUS-guided
coil injection alone. Combined EUS-guided CYA and coiling were found to have better
technical and clinical success rate compared coil embolization alone (99% vs 97%; P <
0.001 and 96% vs 90%; P < 0.001) and CYA alone (100% vs 97%; P < 0.001 and 98% vs
96%; P < 0.001). Similarly, lower adverse events were found to be with EUS-guided
CYA and coil combined compared to coil embolization (10% vs 3%; P = 0.057) and
CYA alone (10% vs 21%; P < 0.001)[15]. Given the above results from various studies,
EUS-guided coil embolization and CYA injection combined therapy could be preferred
compared to EUS-guided monotherapy with either coil or CYA injection alone.
Thrombin injection. Recently, a study of eight patients (three with active bleeding
and five as elective prevention) with GFV treated with EUS-guided thrombin injection
was published. About 2/3 of patients with active bleeding had successful hemostasis
and obliteration of varices. All five patients who underwent the procedure for
prevention of future bleeding had complete obliteration of varices. No direct
procedure-related complications were observed. Although this series showed positive
results, further large prospective studies are needed[19].
Ectopic varices: Ectopic varices can develop at any site, including duodenal, small
bowel, colon, rectum, common bile duct, and peristomal, with duodenum ectopic
varices are being the most frequent to bleed[25,28]. Many case reports have described
the use of EUS for variceal bleeding at ectopic sites. Cases of duodenal variceal bleed
treated with EUS-guided coil and CYA have been described without any complications[29].
Rectal varies are reported in 44%-89% of cirrhosis patients because of PH[30]. It can
also be seen in patients with vascular anomalies, mesenteric vein obstruction,
adhesions, and heart failure. However, rectal varices are a lower bleeding risk than
esophageal and GV[11]. EUS can help detect and treat the presence of rectal varices
better than the endoscopy (Table 2). Although most of the data for EUS-guided
intervention for bleeding ectopic varices is based on case reports/series, it is emerging
as a viable option.

Non-variceal GIB
GIB can be due to variceal or non-variceal causes[31]. Standard endoscopic treatments
for non-variceal bleeding include injection (epinephrine), thermal (argon plasma
coagulation, electrosurgical coagulation), and mechanical therapy (such as clipping).
Despite these interventions, rebleeding or refractory bleeding is reported as high as
10%-24% in these patients[31]. EUS-guided therapies are advantageous over
endoscopic therapy due to the ability to directly visualize target vessels buried in the
walls of the organ along with real-time doppler. A literature review of 35 patients who
underwent EUS-guided treatment of non-variceal GIB (NVGIB) showed a favorable
clinical outcome in 32/35 (91.4%) patients, with recurrent bleeding in only three
patients. Moreover, bleeding eventually stopped in all cases. The median follow-up
time was 11 mo, and no complications or adverse events were reported during or after
the procedure[32]. EUS-guided treatment can also be used as an adjunct treatment in
refractory and recurrent disease.

Dieulafoy’s lesions
The first use of EUS-guided therapy for Dieulafoy’s lesion was described in 1996 when
EUS was used to detect and treat eight patients referred for suspicion of Dieulafoy’s
lesion. A large vessel was identified in the stomach wall in all eight patients, which
was treated with adrenaline/polidocanol injection using a sclerotherapy needle. Two
patients had rebleeding during follow-up, one with recurrent bleeding from
Dieulafoy’s lesion and the other from duodenal ulcer. EUS-guided angiotherapy was
described by Levy et al[33] in a case series of five patients with refractory bleeding due
to hemosuccus pancreaticus, Dieulafoy lesion, duodenal ulcer, GI stromal tumor
(GIST), and occult GIB. These patients had failed at least two conventional treatment
options and received an average of 18 units of packed red blood cell transfusions.
Patients were treated by injecting CYA (3-5 mL) or 99% alcohol into a feeding vessel
using a 22G FNA needle under EUS-guidance. Doppler was used to ensuring the
absence of blood flow after treatment. These patients were followed up for a mean 12mo period (range 0.4-23 mo), no rebleeding or complication was reported[33].
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Table 2 Case report studies on endoscopic ultrasound-guided rectal varices treatment
Presenting
symptom

Ref.

Number of
Rectal varices
patients, age,
size
sex

Therapy

Results

Follow
Results on follow up
up

Philips and
Augustine[64],
2017

Rectal
bleeding

1, 48 yr, M

Large rectal
varix

EUS-guided embolization coil
and glue

No further
bleeding

1 mo

No rebleeding

Bazarbashi et al
[65], 2020

Rectal
bleeding

1, 71 yr, M

Large rectal
varices (4 mm in
diameter)

EUS-guided coil embolization

No further
bleeding

6 mo

No bleeding

Mukkada et al
[66], 2017

Rectal
bleeding

1, 65 yr, M

Large rectal
varices

First EUS-guided
sclerotherapy, but unable to
achieve hemostasis, EUS
guided glue

No further
bleeding

1 wk

Rebleeding and then
required EUS-guided
coil embolization

F: Female; M: Male; EUS: Endoscopic ultrasound; N/A: Not applicable.

Law et al[34] performed EUS-guided hemostatic interventions between June 2003 to
May 2014 for 17 patients with refractory NVGIB. Causes of GIB were GIST, colorectal,
vascular malformations, Dieulafoy lesions, duodenal ulcers, masses or polyps, rectally
invasive prostate cancer, pancreatic pseudoaneurysms, ulcerated esophageal cancer,
and ulceration after Roux-en-Y gastric bypass. These patients were treated with
epinephrine, 99% ethanol, coil embolization, band ligation, hyaluronate, and CYA
using a therapeutic curvilinear echoendoscope with a 22G standard FNA needle. On
median follow-up of 12 mo (range 3 wk-120 mo), 15/17 (88%) patients didn’t have any
recurrence. However, one patient required repeat EUS-guided band ligation for gastric
Dieulafoy lesion, and another patient with rectally invasive prostate cancer
experienced ongoing bleeding despite a decrease in vessel flow after treatment with
99% ethanol injection.

Pseudoaneurysms
Pseudoaneurysms are a known complication of pancreatitis with a risk of rupture and
life-threatening bleeding. The risk of rupture is as high as 50%, with 15%-40% of
mortality after rupture. Gamanagatti et al[35] described a case series of three patients
with pancreatitis-related pseudoaneurysm, which were technically challenging to treat
by the endovascular route. These cases were managed with EUS-guided thrombin
injection, which resulted in complete thrombosis of the pseudoaneurysms. There were
no immediate or late complications on follow-up. In a prospective study, eight patients
with symptomatic visceral artery pseudoaneurysm who were unable to undergo
angioembolization underwent EUS-guided thrombin injection for pseudoaneurysm.
Out of eight patients, 5 had pseudoaneurysm of the splenic artery, 2 had pseudoaneurysm of the hepatic artery, and one patient had pseudoaneurysm of the
gastroduodenal artery. Five patients with splenic artery and gastroduodenal artery
aneurysms had chronic pancreatitis due to alcohol abuse. The pseudoaneurysm's
median size was 2.9 cm × 2.6 cm (range 1.8 cm × 1.9-4 cm × 5 cm), and the median
dose of thrombin injected was 400 IU (200-500 IU). Thrombin was injected under EUS
guidance with 100% technical success. Repeat EUS after 72 h and 4 wk showed
obliteration of pseudoaneurysm in all patients. Whereas on median six mo (1-9 mo)
follow up, EUS showed obliterated pseudoaneurysm in 7 patients, and one patient had
recurrence requiring recanalization after 6 wk[36]. There are few case reports
describing the use of EUS-guided intervention for pseudoaneurysms (Table 3).

GIST
EUS is traditionally used to evaluate GI luminal tumors and obtain a tissue diagnosis.
Bleeding GISTs are traditionally managed by either surgical resection, radiologic
embolization, or rarely with endoscopic therapies like hemoclips and endoloop®
ligation. In an elderly patient with a bleeding ulcer due to GIST who was not a
candidate for surgery due to comorbidities, EUS-guided angiotherapy was done. A
deep vessel was identified to bleeding GIST ulcer via echoendoscope, and the target
vessel was treated with CYA, which stopped bleeding. Doppler confirmed the absence
of vascularity, and the patient had no further bleeding at 6 mo follow-up[37]. In a
study, 32 consecutive patients with submucosal tumors of the upper GI tracts
underwent EUS examination with either radial or linear echoendoscope with color and
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Table 3 Case report studies on endoscopic ultrasound-guided treated for pseudoaneurysm
Presenting
symptom

Ref.

Number of
Pseudoaneurysm
patients,
artery
age and sex

Therapy

Results

Follow Results on
up
follow up

Gamanagatti
et al[35], 2015

Pancreatitis with
upper GI bleed in all
three cases

3; 56, 45 and
30 yr; M

Gastroduodenal artery1, splenic artery for 2
patients

EUS-guided
thrombin injection

Bleeding stopped,
Obliteration of
pseudoaneurysm

1 mo

No bleeding

Robb et al[67],
2012

Infected
pseudoaneurysm

1, 54 yr, M

Superior mesenteric
artery branch

EUS-guided
embolization

Obliteration of
pseudoaneurysm

5 mo

Asymptomatic

Somani et al
[68], 2017

Melena

1, 50 yr, M

Gastroduodenal artery

EUS-guided coil
embolization and
thrombin injection

Obliteration of
pseudoaneurysm

2 wk

No further
bleeding

Jhajharia et al
[69], 2018

Chronic pancreatitis,
GI bleed

3; 43, 25 and
55 yr; M

Gastroduodenal artery,
hepatic artery, splenic
artery

EUS-guided
thrombin injection

Obliteration of
pseudoaneurysm

14 d

No rebleeding

F: Female; M: Male; EUS: Endoscopic ultrasound; GI: Gastrointestinal; N/A: Not applicable.

Doppler capabilities: 51.4% had a discrepancy between suspected endoscopic and EUS
diagnosis, 83.3% of malignant GISTs had significant intratumoral vessels seen on
doppler or color EUS compared to 28% in benign GIST. Three patients were found to
have vascular lesions, hemangioma on color Doppler EUS. In two patients, these
lesions were treated with EUS-directed therapy consisted of ligation, coagulation,
injection of sclerosing agents, or histoacryl resulting in complete eradication of lesions.
One patient required surgery due to the severity of the bleeding. The patients
remained asymptomatic on a mean follow-up of 48 mo[38].
Although the results of EUS-guided therapies in non-variceal bleeding are
encouraging, most of the data is based on case reports and case series. No studies have
compared EUS treatment with other management therapies such as endoscopic,
surgical, and interventional radiology. Further large-scale studies comparing the
standard treatment are needed. At present, EUS-guided therapies are available only at
high-level care centers when other treatment options fail.

EUS-GUIDED PV INTERVENTIONS
PV access and pressure measurement
PV access can help to manage patients with the hepatobiliary diseases and PH. PV is
not easy to access with traditional routes. Nevertheless, PV can easily be seen from the
stomach and duodenum with EUS and accessed using a standard FNA needle. EUS,
along with doppler, is used for needle puncture and withdrawal without hemorrhage
[39]. Initial studies of EUS-guided PV access were performed in animals.
The measurement of PH can help to stage cirrhosis and thus prognosis. Portal
pressure gradient (PPG) reflects the degree of PH. PPG ≥ 10 mmHg is associated with
esophageal varices, and ≥ 12 mmHg is associated with variceal bleeding[40].
Currently, PH is evaluated by indirect measurement of the hepatic venous pressure
gradient (HVPG), which poorly correlates with directly measured portal pressure in
presinusoidal PH. Presinusoidal PH can be seen in the case of PV thrombosis, schistosomiases, and non-cirrhotic portal fibrosis[41-43].
The first human pilot study conducted to measure EUS-guided PPG measurement
included 28 patients with a history of liver disease or suspected cirrhosis. The PV and
hepatic vein (or inferior vena cava) were punctured with a 25G FNA needle under
EUS guidance either through a transgastric or transduodenal approach. A 100%
technical success with no complications was reported. PPG measurement showed a
correlation with clinical and endoscopic parameters of PH, including the presence of
varices (P = 0.0002), portal hypertensive gastropathy (P = 0.007), and thrombocytopenia (P = 0.036). PPG was shown to increase in patients with high clinical evidence
of cirrhosis (P = 0.005)[40]. This study showed that the EUS-guided PPG measurement
is safe in humans and further large clinical trials to evaluate safety and efficacy,
especially compared to standard HVPG measurement methods, as intrahepatic
portosystemic shunt (IPSS).
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Transjugular IPSS (TIPS) is performed by interventional radiologists to reduce the
PPG. TIPS decompresses the portal system and reduces complications due to PH, such
as recurrent variceal bleeding and refractory ascites. It is usually performed in patients
with refractory variceal bleed. TIPS involves catheter advancement and guidewire
through the right heart and then inferior venacava (IVC) via transjugular route. It can
expose patients to unintentional carotid or tracheal puncture, cardiac arrhythmias, and
pneumothorax. Also, the transjugular approach for TIPS can be technically challenging
in patients with IVC and hepatic vein obstruction, including Budd-Chiari syndrome.
EUS-guided IPSS offer benefit as it does not involve heart catheterization, avoiding the
related complications[44-48].
A study was conducted to create IPSS using lumen opposing metal stent (LAMS) in
a porcine model. PV was accessed by puncturing through the stomach wall and IVC
with a 19G needle under EUS guidance. A distal flange of the stent was deployed in
the PV and the proximal flange in IVC. Gross necropsy of all five animals showed the
correct placement of a stent and no tissue injury or hematoma[49]. Although IPSS has
shown promising results in animal models, more studies are needed to evaluate the
efficacy and safety of this technique.

PV embolization
Preoperative PV embolization induces the atrophy of the embolized liver lobe to be
resected and compensatory hypertrophy of non-embolized remnant liver to increase
future liver volume to prevent postoperative liver dysfunction. It is performed in
patients with hepatocellular carcinoma (HCC), intrahepatic or hilar cholangiocarcinoma receiving extensive liver resection[25,50]. Liver resection should be performed
2 to 6 wk after PV embolization as compensatory hypertrophy of non-embolized
remnant liver occurs in 6 wk with a maximum in the first 2 wk after the procedure.
Proceduralists should have meticulous knowledge of liver and portal venous system
anatomy before performing this procedure[51]. Presently it is performed through a
percutaneous transhepatic approach by vascular interventional radiologist[50]. In a
live porcine model to study EUS-guided selective intrahepatic PV embolization, PV
was punctured with a 19G FNA needle under EUS guidance, the first coil, and then
CYA was injected through the same FNA needle. Doppler was used to evaluating the
blood flow. Coil and CYA delivery had a success rate of 88.9% and 87.5%, respectively.
In one case, the embolized coil migrated to hepatic parenchyma, and CYA injection
failed one case due to the early clogging of CYA in the FNA needle. One wk later,
postoperative necropsy showed total occlusion of selected PV with embolus and no
evidence of damage to any other organ[50]. Further studies are needed comparing the
EUS-guided PV embolization to the percutaneous approach and evaluate the longterm effects.

Portal venous blood sampling
Pancreaticobiliary cancers (PBCs) are usually at advance to late stages at the time of
diagnosis. Circulating tumor cells (CTCs) circulate from the primary tumor to distant
sites through vascular supply, and their number is usually low in peripheral blood. In
the case of PBCs, CTCs can be detected in the portal circulation before the peripheral
blood and can be used to detect metastasis[25,52,53].
In a single-center cohort study, 18 patients with suspected PBCs had blood aspirated
from PV via a 19G FNA needle through a EUS-guided transhepatic approach. Paired
peripheral blood samples were also collected. Epithelial-derived CTCs were isolated.
CTCs were detected from PV samples in all 18 patients (100%), whereas only in
peripheral blood samples of four patients (22.2%). These CTCs isolated from PV can
also provide sufficient cells to do genomic and proteomic tumor profiling[52].
In another study performed on patients undergoing pancreaticoduodenectomy for
presumed periampullary or pancreatic adenocarcinoma without metastatic disease, PV
and peripheral venous samples were collected simultaneously at the time of surgery.
Sixty patients were monitored postoperatively every three months for one year with
imaging for liver metastasis. CTCs were detected in 58% of cases in PV blood
compared to 40% in a peripheral blood sample (P = 0.0098). CTCs count was also high
PV sample than peripheral blood sample (mean, 230.1 vs 71.7, P = 0.0002). Liver
metastasis was detected in 11 of 13 patients with high portal CTCs count (> 112 CMx
Platform estimated CTCs in 2 mL blood) compared to 6 of 47 patients with low portal
CTCs count (P < 0.0001) at 6-mo follow-up after surgery. The results of this study
concluded that the CTCs can be used as a predictor for liver metastases within six
months after surgery in patients undergoing pancreaticoduodenectomy for presumed
periampullary or pancreatic adenocarcinoma[53]. Unfortunately, PV blood sampling
with an evaluation of CTCs is only available in the limited number of specialized
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tertiary care centers. Further larger studies are needed to ensure the efficacy and safety
of the procedure before making it standard of care to predict hepatic metastasis in
patients with pancreatic adenocarcinoma.

FNA of PV thrombus
PV thrombosis due to tumor invasion by direct venous extension or metastasis is seen
in up to 70% of cases of HCC[54]. Patients with HCC can also have nontumor (bland)
thrombosis of PV. It could be challenging to differentiate PV tumor thrombosis (PVTT)
from bland PV thrombosis based on routine radiographic imaging. It is essential to
diagnose PVTT as it is a poor prognostic sign, and curative resection or liver
transplantation is contraindicated if the patient has PVTT. Transabdominal
ultrasound-guided FNA has limited utility due to the difficulty of sample thrombus in
the central main PV without contaminating with normal hepatocytes or liver mass,
which can affect results. Furthermore, this procedure can have several complications,
including vascular injury, pseudoaneurysm formation, and bile duct injury. EUSguided FNA can directly access the extrahepatic PV without passing the needle
through liver tissue[54,55]. Several case reports of EUS-guided FNA of PV thrombosis
for diagnosis and staging of HCC even in patients when imaging did not show any
liver mass[54-56].

Liver-directed PV injection chemotherapy
The liver is a common site of metastasis from other primary tumors. Patients with
diffuse liver metastasis usually resort to palliative systemic chemotherapy given
limited options available. It is hypothesized that the direct injection of chemotherapy
into PV may increase the drug level in hepatic tissue while decreasing systemic side
effects[25,57]. In a study, EUS-guided portal injection chemotherapy (EPIC) was
performed by injecting irinotecan (100 mg) loaded microbeads by using a 22G FNA
needle, and the control group had saline injected to PV and irinotecan (100 mg)
injected into the jugular vein. EPIC resulted in twice a level of irinotecan in hepatic
tissue after 1 h. and half the irinotecan level in plasma after 15 min[57]. These animal
studies showed that EPIC could be an option for patients with diffuse liver metastasis;
however, no human studies are available currently.

ROLE IN TUMOR DIAGNOSIS
Invasion of the vascular structures by tumor impacts staging and therapeutic options,
including tumor resectability. Vascular invasion can often be diagnosed based on
radiographic imaging like CT, magnetic resonance imaging (MRI), or positron
emission tomography scans. However, sometimes it is difficult to judge based on the
imaging as in pancreatic ductal adenocarcinoma. Similarly, tumor thrombi can be
challenging to differentiate from bland thrombi based on imaging. EUS-guided FNA
and elastography can be helpful in these cases.
In a retrospective study, forty-four patients with pancreatic ductal adenocarcinoma
underwent dynamic CT and EUS, EUS-B mode imaging was taken, and also EUS
elastography was done in all cases. Sensitivity, specificity and accuracy (95%CI) for
vascular invasion were 0.733, 0.697 and 0.708 on dynamic CT; 0.733, 0.606 and 0.646 in
EUS B-mode; and 0.917, 0.900 and 0.906 in EUS elastography. EUS-B mode and EUS
elastography should be considered in patients with pancreatic ductal adenocarcinoma,
where dynamic cannot detect vascular invasion[58].

ACCESS TO NON-GI STRUCTURES
The heart and pulmonary vascular systems can be easily accessed via EUS because of
their proximity to the esophagus. Transesophageal echocardiography is routinely done
in cardiac patients for various conditions[59]. Fritscher-Ravens et al[60] conducted a
study where they performed EUS-guided puncture of the heart in a porcine model
using a linear array echoendoscope followed by three clinical cases. In the porcine
study, 22- and 19-gauge EUS needles were used to access the left atrium, left ventricle,
coronary arteries, and aortic valve. In the porcine group, procedures performed
included needle biopsy of cardiac muscle; contrast injection into the left atrium,
ventricle, coronary arteries; radiofrequency ablation of aortic and mitral valves; and
passage of a guidewire. No arrhythmias were reported during the procedures. During
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necropsy, penetration sites were identified, but they were unremarkable in
appearance; no bleeding or hematoma was noticed. Subsequently, EUS-guided cardiac
access was performed in three patients. In two patients, pericardial fluid was aspirated
for diagnostic purposes using a 22-gauge EUS needle, and the third patient had the
FNA of atrial mass. No adverse events were observed after procedures in these
patients.
Somani et al[61] described EUS-guided thrombolysis of pulmonary artery thrombus
in a 57-year-old patient who presented with shortness of breath, shock, and acute
abdominal pain. The patient had a superior mesenteric vein and right pulmonary
artery thrombus. Given the shock state and history of recent hemorrhagic stroke, EUSguided thrombolysis of pulmonary artery thrombus was done with Tenecteplase using
25G needle. Repeat EUS after 48 h and one before 15 d showed a reduction in the
volume of thrombus.

Gaps in knowledge
The GI tract provides access to several vascular structures in the mediastinum,
abdominal, and pelvis. Currently, most vascular interventions are done by an
interventional radiologist through a percutaneous route. EUS provides access to most
of the vasculature through the GI tract and the ability to do real-time interventions.
Various studies have shown promising results for the safety, clinical and technical
success of EUS-guided vascular intervention concluding that it should be considered
either as first-line therapy or when conventional treatment fails. Although results are
promising, it is based on case reports and series except in GV management, for which
relatively more extensive studies are available.
Given that most data is available from case studies and series, it increases the risk of
selection bias. Furthermore, these studies are available from tertiary care centers due
to the limited availability of EUS and specialist trained in echoendoscope. EUS will
eventually offer a less invasive and safer approach to various vascular interventions as
this field expands further.

CONCLUSION
The GI tract provides a unique window to vascular structures in the mediastinum and
abdomen, which can be accessed through FNA needle. Various studies have shown
promising results for the safety, clinical and technical success of EUS-guided vascular
intervention concluding that it should be considered either as first-line therapy or
when conventional treatment fails. Although results are promising, it is based on case
reports and series except in GV management for which relatively more extensive
studies are available. Given that most data is available from case studies and series, it
increases the risk of selection bias. Furthermore, these studies are available from
tertiary care centers due to the limited availability of EUS and specialist trained in
echoendoscope. As this field advances, EUS will offer a less invasive and safer
approach to various vascular interventions.
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